Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

4(57.1%)

N/A

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 3(4)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06888063Phase 2Recruiting

Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery

Role: collaborator

NCT05503108Phase 3Suspended

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Role: collaborator

NCT04272931Not ApplicableUnknown

DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE

Role: collaborator

NCT02407795Not ApplicableTerminated

Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases

Role: collaborator

NCT03474341Unknown

Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Role: collaborator

NCT00442637Phase 3Unknown

Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma

Role: collaborator

NCT00208546Phase 3Completed

Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Role: collaborator

NCT00312000Phase 3Completed

Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma

Role: collaborator

All 8 trials loaded